Focus

Nature Biotechnology 20th Anniversary

Nature Biotechnology is 20! We have brought together a collection of Features celebrating two decades of the science and business of biotech, with an eye on the future.

Top

Editorial

Nature Biotechnology 20th Anniversary Issue

Breaking out of the bubble p213

doi:10.1038/nbt.3517

The biotech community has made remarkable progress over the past 20 years. Now it needs to break out of its bubble.


Top

Features

Nature Biotechnology 20th Anniversary Issue

Estimating the biotech sector's contribution to the US economy pp247 - 255

Robert Carlson

doi:10.1038/nbt.3491

US biotech sector revenue is estimated to have grown on average >10% each year over the past decade—much faster than the rest of the economy. A more comprehensive assessment of biotech's economic contribution, however, will require improved data collection, classification and analysis.


Nature Biotechnology 20th Anniversary Issue

20 years of Nature Biotechnology research tools pp256 - 261

Anna Azvolinsky, Laura DeFrancesco, Emily Waltz & Sarah Webb

doi:10.1038/nbt.3507

Authors of some of the most highly cited Nature Biotechnology papers that describe research tools discuss their work and challenges for their fields.


Nature Biotechnology 20th Anniversary Issue

20 years of Nature Biotechnology biomedical research pp262 - 266

Anna Azvolinsky, Charles Schmidt, Emily Waltz & Sarah Webb

doi:10.1038/nbt.3509

Authors of some of the most highly cited Nature Biotechnology biomedical papers from the past 20 years discuss their work and challenges for their fields.


Nature Biotechnology 20th Anniversary Issue

20 years of Nature Biotechnology bioengineering research pp267 - 269

Laura DeFrancesco, Charles Schmidt & Emily Waltz

doi:10.1038/nbt.3508

Authors of some of the most highly cited Nature Biotechnology nonbiomedical papers from the past 20 years discuss their work and challenges for their fields.


Nature Biotechnology 20th Anniversary Issue

Voices of biotech pp270 - 275

Ido Amit, David Baker, Roger Barker, Bonnie Berger, Carolyn Bertozzi, Sangeeta Bhatia, Alessandra Biffi, Francesca Demichelis, Jennifer Doudna, Steven F Dowdy, Drew Endy, Moritz Helmstaedter, Howard Junca, Carl June, Sasha Kamb, Anastasia Khvorova, Dae-hyeong Kim, Jin-Soo Kim, Yamuna Krishnan, Melike Lakadamyali, Tuuli Lappalainen, Sharon Lewin, James Liao, Nick Loman, Emma Lundberg, Lee Lynd, Cathie Martin, Ira Mellman, Atsushi Miyawaki, Christine Mummery, Karen Nelson, Jeanne Paz, Pamela Peralta-Yahya, Paola Picotti, Kornelia Polyak, Kristala Prather, Jun Qin, Stephen Quake, Aviv Regev, John A Rogers, Reshma Shetty, Morten Sommer, Molly Stevens, Gustavo Stolovitzky, Masayo Takahashi, Fuchou Tang, Sarah Teichmann, Maria-Elena Torres-Padilla, Leena Tripathi, Praveen Vemula, Greg Verdine, Frank Vollmer, Jun Wang, Jackie Y Ying, Feng Zhang & Tian Zhang

doi:10.1038/nbt.3502

Nature Biotechnology asks a selection of researchers about the most exciting frontier in their field and the most needed technologies for advancing knowledge and applications.


Nature Biotechnology 20th Anniversary Issue

Community crystal gazing pp276 - 283

Anu Acharya, Kate Bingham, Jay Bradner, Wylie Burke, R Alta Charo, Joel Cherry, André Choulika, Tony Coles, Robert Cook-Deegan, Stanley T Crook, Emilia Díaz, Brent Erickson, L Val Giddings, Sebastian Eriksson Giwa, James C Greenwood, Vishal Gulati, Sam Hall, John Harris, Jamie Heywood, Colin Hill, Jeremy Levin, Adina Mangubat, John Maraganore, Giovanni Mariggi, Barbara J Mazur, Amy L McGuire, Nathalie Moll, Jonathan Moreno, Gail Naughton, Lita Nelsen, Jane Osbourn, Daniel Perez, John Reed, Eric Schmidt, Vicki Seyfert-Margolis, Paul Stoffels, Jørgen Thorball, Tara O'Toole, Indrek Vainu, Sander van Deventer, Elias Zerhouni & Daphne Zohar

doi:10.1038/nbt.3515

A selection of individuals from the biotech ecosystem give their views on the challenges facing the sector over the coming years.


Nature Biotechnology 20th Anniversary Issue

When biotech goes bad pp284 - 291

John Hodgson

doi:10.1038/nbt.3510

A look at 20 years of the dark side of biotech.


Patents

Nature Biotechnology 20th Anniversary Issue

The changing life science patent landscape pp292 - 294

Arti K Rai & Jacob S Sherkow

doi:10.1038/nbt.3504

What have we learned from 20 tumultuous years of patent law in the life sciences? Is patenting likely to be as important for the industry in the future?


Top